Working… Menu

ALGRX 4975 in the Treatment of Tennis Elbow

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00130949
Recruitment Status : Completed
First Posted : August 17, 2005
Last Update Posted : December 20, 2006
Information provided by:
AlgoRx Pharmaceuticals

Brief Summary:
Tennis elbow is a painful condition that results from repetitive arm movement with overuse of muscles, e.g. when playing tennis. A single injection of ALGRX 4975 has the potential to reduce pain for a period of weeks to months. This study will test the efficacy and safety of ALGRX 4975 in the treatment of patients with tennis elbow.

Condition or disease Intervention/treatment Phase
Tennis Elbow Drug: ALGRX 4975 Phase 2

Detailed Description:

Lateral epicondylitis (tennis elbow) is a painful condition that affects 4 to 7 adults per 1000 annually and tends to involve the subject's dominant side. It typically results from repetitive arm movement with over use of muscles leading to small tears in the tendons attaching muscles of the forearm to the epicondyles that may progress to tendonitis. Pain on or around the lateral epicondyle may radiate down the subject's arm. Gripping or extending the wrist often intensifies the pain.

More than 40 possible treatments have been proposed, reflecting a lack of consensus about optimal management. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat tennis elbow, but there are no trials to date that have compared them with other painkillers and one study found no clinically important benefit over placebo. Use of corticosteroid injections provides mixed results in relief of pain and at times insufficient evidence to support their use. Although complications associated with steroid injection are relatively uncommon, when a complication does occur, it can result in severe and disabling consequences for the subject. A small proportion of subjects fail to respond to only one injection of corticosteroid and some subjects who initially improved at four weeks had worse symptoms by six months.

This study has been designed to evaluate the safety and efficacy of a single soft tissue injection of ALGRX 4975 at a dose of 100 µg in comparison to placebo in subjects with acute LE.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase II, Exploratory Evaluation of ALGRX 4975 in Subjects With Acute Lateral Epicondylitis
Study Start Date : November 2004
Study Completion Date : November 2005

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Pain induced by resisted wrist dorsiflexion 4 weeks after treatment

Secondary Outcome Measures :
  1. Pain induced by resisted wrist dorsiflexion (other than 4 weeks)
  2. Grip strength
  3. Pain experienced during the grip strength test
  4. Pain in elbow over previous 24 hours
  5. Effect on work
  6. Tenderness elicited by investigator or designee
  7. Subjects' global impression of change
  8. Secondary outcomes are evaluated at 1, 2, 4, 8 and 12 weeks.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Acute lateral epicondylitis (LE) of less than 3 months duration (subjects with recurrent acute LE may be included).
  • A screening and baseline severity of pain on resisted wrist dorsiflexion score of moderate or greater intensity.
  • Lidocaine responsive.
  • A systolic and diastolic blood pressure not greater than 140 and 95 mm Hg, respectively.

Exclusion Criteria:

  • Any clinically significant form of joint disease, elbow trauma or neuromuscular disorder at the elbow, other than acute LE.
  • Physiotherapy treatment within the preceding 2 weeks, prior to Visit 1.
  • Any systemic or local corticosteroids within the preceding 3 months, except nasal or inhaled steroids at less than or equal to 1000 mcg/day.
  • A medical condition other than LE that requires the use of a pain medication.
  • A peripheral sensory or motor neuropathy involving the upper extremities.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00130949

Layout table for location information
Ortopedicko-Traumatologicka Klinika
Kosice, Slovakia, 040 11
Sponsors and Collaborators
AlgoRx Pharmaceuticals
Layout table for investigator information
Principal Investigator: Gabriel Vasko, MD PhD Ortopedicko-Traumatologicka Klinika, Kosice, Slovak Republic
Layout table for additonal information Identifier: NCT00130949    
Other Study ID Numbers: 4975-2-005-2
Eudra CT No : 2004-001000-12
First Posted: August 17, 2005    Key Record Dates
Last Update Posted: December 20, 2006
Last Verified: August 2005
Keywords provided by AlgoRx Pharmaceuticals:
Acute lateral epicondylitis
Tennis elbow
Additional relevant MeSH terms:
Layout table for MeSH terms
Tennis Elbow
Elbow Tendinopathy
Muscular Diseases
Musculoskeletal Diseases
Arm Injuries
Wounds and Injuries
Tendon Injuries